I-125 seeds brachytherapy combined with immunotherapy for MET amplification in non-small cell lung cancer from clinical application to related lncRNA mechanism explore: a case report
Authors:
Open Access
- 14 June 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1176083
Abstract
Advanced non-small cell lung cancer (NSCLC) with MET amplification primarily relies on MET inhibitors for treatment, but once resistance occurs, the available treatment options are limited and the prognosis is typically poor. A 57-year-old man with advanced NSCLC and C-MET amplification was initially treated with crizotinib but developed progressive disease. After the antirotinib treatment, he achieved a partial response for a year. Genetic testing showed high PD-L1 expression, and he was treated with pembrolizumab and chemotherapy for 3 months, with partial response. Maintenance therapy with pembrolizumab and local I-125 seeds brachytherapy (ISB) was given after the lung lesion progressed but other lesions remained stable. The therapy resulted in significant resolution of the right upper lung lesion. It demonstrates the effectiveness of ISB-ICI combination in treating MET amplification advanced NSCLC. Ongoing research and treatment innovation are important in managing advanced NSCLC with complex genetic aberrations. To explore the candidate mechanism of ISB therapy response, we download public genetic data and conduct different expression Lncrnas analysis and pathway analysis to discover radiotherapy related sensitive or resistance lncRNAs and pathways, we found that AL654754.1 is a key lncRNA with radiotherapy response, and it also include in classical p53 and Wnt signaling pathway. Overall, the clinical case reports, combined with the exploration of underlying mechanisms, provide positive guidance for the precise treatment of lung cancer.Keywords
This publication has 21 references indexed in Scilit:
- PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersAnnals of Oncology, 2018
- EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to DacomitinibJournal of Thoracic Oncology, 2018
- Targeting the tumour stroma to improve cancer therapyNature Reviews Clinical Oncology, 2018
- Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the LungJournal of Thoracic Oncology, 2017
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the InevitableLung Cancer, 2017
- Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non–Small-Cell Lung CancerClinical Lung Cancer, 2016
- Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimensOncoImmunology, 2014
- Preliminary Reports Comparison of the GTV coverage by PTV and isodose of 90% in 2D and 3D planning during endobronchial brachytherapy in the palliative treatment of patients with advanced lung cancer. Pilot studyJournal of Contemporary Brachytherapy, 2012
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010
- Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors*International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993